Overview:
Epilepsy
can be classed as a major neurological disorder where the brain activity
becomes abnormal and triggers unusual behavior and sensations. The disorder is
discernible in young children and young adults and requires proper attention in
time before it can impact the body in an adverse way.
The Epilepsy Market Share is expected to
reach USD 1.10 Billion by 2032 at 7.2% CAGR during the forecast period 2023-2032.
The regional market is showing ample scope where a high prevalence of the
disease can inspire growth in diverse regions.
In addition, the global market would benefit
from the presence of countries in the African region where various global
bodies are trying to launch initiatives to assist local doctors in curbing the
diseases. However, poor economies can detract the growth rate.
Competitive
Landscape:
MRFR’s analysis of various companies to get close to
factors that can decipher the market growth and assist in the implementation of
several market strategies. The recording of these moves can inspire a better
understanding of the global scenario. Epilepsy Market Players are
GlaxoSmithKline PLC (U.K.),
LivaNova PLC (U.K.),
Medtronic PLC (Ireland),
Eisai Co. Ltd. (Japan),
Pfizer Inc. (U.S.),
NeuroPace Inc. (U.S.),
UCB SA (Belgium),
Johnson & Johnson Services Inc. (U.S.),
Novartis AG (Switzerland),
GW Pharmaceuticals PLC (U.K.),
Abbott Laboratories (U.S.).
These companies are set on a path to solidify their own market stance
and improve scopes for expansion in the coming days.
Segmentation:
The
report on the epilepsy market insights encompasses
segments like by condition, diagnosis & treatment, and end-use to
facilitate an easy understanding of the market and gauge well how the regional
market would shape up in the coming years.
·
By condition, the market report
on epilepsy covers epilepsy drug-resistant/intractable
epilepsy and others. The former had a market share of 29.5% in 2017. The global
market for the segment can provide ample growth opportunities as the
requirement for drug-resistant therapies can trigger better growth. The
‘others’ segment has a market growth possibility of 7.83% CAGR during the
forecast period.
·
By diagnosis and treatment, the market
report on epilepsy includes diagnosis and treatment. The diagnosis segment can
be sub-segmented into blood tests, imaging devices, and others. The treatment
segment includes neurostimulation devices, anti-epileptic
drugs, ketogenic diet, brain surgery, and others. The treatment segment had
66.2% of the global share in 2017. Cost-efficiency can be taken into
consideration to understand market growth possibilities.
·
By end-users, the epilepsy
market can include clinics, hospitals, diagnostic centers, ambulatory surgical
centers, and others. The hospital segment had a market share of 29.3% in 2017.
Regional Analysis:
The
global market, upon considering from a region-specific angle, can be segmented
into North America, Europe, and the Asia Pacific as major contributors. It also
covers Latin America and the Middle East & Africa (MEA) as countries
displaying moderate growth but with the potential to improve scenario. The
Americas has better market coverage and it had almost 41% of the global market
share in 2017. Europe is on a track to display 8.31% CAGR during the forecast
period. The regional market has potential to explore opportunities regarding
research and development, and it is getting backed by the constant influx of
investments. Countries like the UK, France, Germany, and others are
contributing much to take the regional market ahead in the coming years.
The Asia Pacific (APAC) market is showing
opportunities to score well past a valuation mark of USD 2,046.57 million by
2023. Most of the traction to grow forward would come from India, South Korea,
and China where a large population is triggering high ingress of treatments
needed for that.
About US:
Market Research Future (MRFR) enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of Wantstats
Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
No comments:
Post a Comment